Additional considerations on vonoprazan triple therapy for Helicobacter pylori eradication: Implementation challenges and clinical perspectives

Abstract

The vonoprazan (VPZ) triple therapy regimen for Helicobacter pylori (H. pylori) eradication developed by Han et al employs a scientifically rigorous clinical trial design. This multicenter randomized controlled trial establishes a standardized treatment framework aimed at improving H. pylori eradication rates, focusing on simplifying treatment regimens, shortening therapy duration, and optimizing therapeutic outcomes. The core of clinical translation lies in improving drug accessibility, establishing multidimensional safety evaluation systems, and optimizing cost-effectiveness. Conducting regional adaptability studies and comprehensive safety assessments is crucial for enhancing VPZ regimen effectiveness in China’s diverse healthcare environments. This study provides important evidence-based support for optimizing H. pylori treatment strategies in China, though further validation of universal applicability for nationwide implementation remains necessary.

Keywords: Helicobacter pylori; Vonoprazan; Multicenter trial; Regional differences; Clinical implementation

Core Tip: Han et al’s multicenter trial demonstrates vonoprazan triple therapy’s superior efficacy over standard bismuth quadruple therapy for Helicobacter pylori eradication in China, successful nationwide implementation faces critical challenges. Key barriers include limited drug accessibility in primary healthcare settings, higher costs compared to traditional therapies, and significant regional variations in antibiotic resistance patterns across China’s diverse population. The study’s single-province design cannot fully represent national applicability. Addressing these implementation gaps through comprehensive health system research, cost-effectiveness analyses, and multi-regional validation studies is essential for translating these promising clinical findings into improved patient outcomes across China’s heterogeneous healthcare landscape.